Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis
Eleni Efstathiou
Fil Manuguid
Peter Kirkpatrick

Showing results (41-50 of 476) with videos related to

Pageof 48
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Chemotherapy for advanced prostate cancer: 25 years laterChristopher J Logothetis, Randall Millikan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?Christopher J Logothetis, Ana M Aparicio
Nature Reviews. Cancer|January 5, 2005
Osteoblasts in prostate cancer metastasis to boneChristopher J Logothetis, Sue-Hwa Lin
Cancer Research|August 4, 2004
Bortezomib as a potential treatment for prostate cancerChristos N Papandreou, Christopher J Logothetis
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
High-grade prostate cancer and the prostate cancer prevention trialChristopher J Logothetis, Paul F Schellhammer
European Urology|March 27, 2024
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7Christopher J Logothetis, Andrew W Hahn
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W Hahn
European Urology|October 23, 2010
Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumChristopher J Logothetis, Arlene Siefker-Radtke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseCharles J Ryan, Shreya Shah, Eleni Efstathiou, et al.
Future Oncology (London, England)|November 18, 2024
The landscape of androgen deprivation therapies for the treatment of advanced prostate cancerNeal D Shore, Michael S Cookson, Eleni Efstathiou
Pageof 48

Showing results (41-50 of 476) with videos related to

Sort By:
Pageof 48
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Chemotherapy for advanced prostate cancer: 25 years laterChristopher J Logothetis, Randall Millikan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?Christopher J Logothetis, Ana M Aparicio
Nature Reviews. Cancer|January 5, 2005
Osteoblasts in prostate cancer metastasis to boneChristopher J Logothetis, Sue-Hwa Lin
Cancer Research|August 4, 2004
Bortezomib as a potential treatment for prostate cancerChristos N Papandreou, Christopher J Logothetis
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
High-grade prostate cancer and the prostate cancer prevention trialChristopher J Logothetis, Paul F Schellhammer
European Urology|March 27, 2024
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7Christopher J Logothetis, Andrew W Hahn
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W Hahn
European Urology|October 23, 2010
Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumChristopher J Logothetis, Arlene Siefker-Radtke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseCharles J Ryan, Shreya Shah, Eleni Efstathiou, et al.
Future Oncology (London, England)|November 18, 2024
The landscape of androgen deprivation therapies for the treatment of advanced prostate cancerNeal D Shore, Michael S Cookson, Eleni Efstathiou
Pageof 48